Journal Guide
Cancer Cell Impact Factor 44.5: Publishing Guide
The highest-impact dedicated cancer research journal: where systems-level thinking meets patient-centered discovery
44.5
Impact Factor (2024)
~8-10%
Acceptance Rate
~5 days to desk decision; ~8 weeks to first decision after review
Time to First Decision
What Cancer Cell Publishes
Cancer Cell publishes research that advances a systemic understanding of cancer as a dynamic interplay between tumor cells, microenvironment, microbiota, nervous system, and host physiology. At IF 44.5, it is the highest-impact dedicated cancer research journal in the world - above Nature Cancer (28.5) and Cancer Discovery (~29). The editorial vision under EIC Steve Mao is explicitly 'systems-level': stop thinking of the cancer cell as an isolated entity and start thinking of cancer as a system.
- Basic cancer biology with patient-centered relevance
- Tumor microenvironment: immune cells, stroma, vasculature, microbiota interactions
- Translational research: bench-to-bedside AND bedside-to-bench
- Mechanism-based proof-of-principle clinical studies
- Multi-omics and computational biology (single-cell, spatial transcriptomics, AI/ML)
- Cancer neuroscience: nervous system-tumor interactions (emerging editorial focus)
Editor Insight
“Cancer Cell is where you go when you have not just discovered something about cancer, but explained why it matters for patients. The journal's 'full-picture view of cancer' philosophy is not marketing - it reflects a real editorial preference for papers that think beyond single pathways and isolated cells. If your work connects the tumor to its microenvironment, to the whole organism, and ideally to a therapeutic implication, you are speaking Cancer Cell's language. The negotiated revision process is genuine: editors want to help you tell the best version of your story.”
What Cancer Cell Editors Look For
Conceptual advance over existing literature
Not 'more data' but fundamentally new understanding. Editors do PubMed searches to compare your paper against what already exists. If they cannot see the leap forward from your abstract, it is a desk reject.
Patient-centered relevance, even for basic work
The editors have said it directly: 'Even if it is a basic question, it still needs to have some relevance to the patient, to the clinic.' Pure cell biology using cancer models without cancer-specific insight is not a Cancer Cell paper.
A full-picture view of cancer as a system
Papers that consider the cancer cell within its microenvironment, as part of a whole organism, are favored. Reductionist one-gene/one-pathway studies face an uphill battle unless the insight is extraordinary.
Use of field-changing technologies
AI, spatial multi-omics, single-cell sequencing, functional genomics are explicitly encouraged. The editors see these as tools for decoding cancer's complexity, not just fashionable techniques.
Bidirectional translation
Bench-to-bedside is valued. But so is bedside-to-bench: taking a clinical observation and tracing it back to a mechanism. Cancer Cell wants the complete translational loop.
Strong mechanistic insights
This remains the journal's hallmark from its founding in 2002. Understanding WHY something happens in cancer, not just THAT it happens, is the minimum threshold.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past Cancer Cell's editorial review:
Submitting 'cell biology using cancer models'
The editors explicitly distinguish this from cancer biology. If your paper studies a basic cell biology question that happens to use cancer cell lines but does not advance cancer understanding specifically, it will be desk-rejected.
Linear, reductionist signaling pathway studies
Gene A activates gene B which activates gene C: this framework feels dated to Cancer Cell editors. They want systems-level thinking and context-dependent biology.
No patient relevance
Even mechanistically brilliant papers need at least a line of sight to clinical significance. A beautiful mouse study with zero connection to human cancer is a hard sell.
Weak cover letter that does not articulate the advance
Your title and abstract appear in the daily 'editorial pack' that ALL editors see first. The cover letter is where you frame the conceptual advance. Generic cover letters get generic responses.
Insufficient novelty or being scooped
Editors do PubMed searches when evaluating your paper. If closely parallel work was recently published, you need to clearly articulate what is different and what is new.
Narrow impact that only interests ultra-specialists
Cancer Cell serves the entire cancer research community. Findings too specialized for the broad readership get redirected to Cell Reports or other Cell Press journals.
Does your manuscript avoid these patterns?
The quick diagnostic reads your full manuscript against Cancer Cell's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from Cancer Cell Authors
Pre-submission inquiries are encouraged and actually read
Email cancer@cell.com. The editors will give honest feedback on fit before you invest time in formatting. This is one of the most underused features at Cancer Cell.
Editors attend conferences to scout papers
The deputy editor has said: 'Maybe I saw this presented at a meeting, or maybe I talked to the authors about this.' Presenting at AACR, ASCO, or EMBO can put you on their radar before you submit.
The editorial team is very small - only ~5 editors
Steve Mao (EIC), Montserrat Rojo de la Vega (Deputy), Zhaodong Li, Feline Dijkgraaf (Scientific Editors), and Cansu Cirzi (shared with Trends in Cancer). Each editor handles many papers and knows their areas deeply.
Revision plans are negotiated - this is unique to Cancer Cell
After review, editors discuss with authors which reviewer points to prioritize. Not all points need equal treatment. Editors help you focus on the main storyline. This collaborative approach is Cancer Cell's most distinctive feature.
Typically only ONE major revision round
If the revision does not satisfactorily address concerns, the paper is transferred to another Cell Press journal, not given another chance. Get it right the first time.
The Cell Press transfer system is built into the process
Papers rejected from Cancer Cell can transfer with reviews to Cell Reports, Cell Reports Medicine, or iScience. This saves months. Think of your Cancer Cell submission as entering the Cell Press ecosystem, not just one journal.
All accepted papers undergo image detective scans
Image integrity is checked by software before formal acceptance. If there are any manipulation concerns, address them proactively. This is standard at Cell Press.
Reviews and Perspectives are mostly commissioned
Unsolicited review submissions rarely succeed. Better approach: send a pre-submission inquiry proposing a review topic. If editors are interested, they will commission it.
The Cancer Cell Submission Process
Pre-submission inquiry (recommended)
Response within 1-2 weeksEmail cancer@cell.com with a brief description of your work. Editors will tell you if it is a good fit before you invest time in full formatting.
Full submission via Editorial Manager
Paper appears in editors' daily 'editorial pack'Manuscript in STAR Methods format, graphical abstract, highlights (≤4 bullet points, ≤85 characters each), eTOC blurb, cover letter explaining the conceptual advance.
Editorial triage (~5 days)
~5 business daysHandling editor assigned; reads full paper, writes notes, consults literature. Team discussion, then decision to send for review or desk reject. ~75-85% desk rejection.
Peer review
~8 weeks total from submission to first decisionHandling editor identifies reviewers by expertise, avoiding competitors. Typically 2-3 reviewers with ~3-week turnaround. Editors summarize reviewer comments and prepare decision.
Negotiated revision plan (unique to Cancer Cell)
Timeline agreed upon with editorsEditors discuss with authors which reviewer points are key versus optional. Mutually agreed timeline set. This collaborative process is Cancer Cell's signature approach.
Publication
Total: typically 6-12 months from submission to publication~3.6 weeks after acceptance. All content becomes freely accessible after 12 months (delayed open access). Gold OA available at $10,400.
Cancer Cell by the Numbers
| 2024 Impact Factor(Clarivate JCR; highest of any dedicated cancer research journal) | 44.5 |
| H-index | 416 |
| CiteScore(Scopus) | 41.9 |
| Estimated submissions per year | ~2,500-3,500 |
| Desk rejection rate | ~75-85% |
| Time to desk decision | ~5 days |
| Time to first decision after review | ~8 weeks |
| Gold OA APC (optional)(Free after 12 months regardless) | $10,400 USD |
Before you submit
Cancer Cell accepts a small fraction of submissions. Make your attempt count.
The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Cancer Cell. ~30 minutes.
Article Types
Research Article
≤7,000 words, up to 8 figures/tablesPrimary research: basic, translational, or clinical. Must include STAR Methods, graphical abstract, and highlights.
Resource
Similar to Research ArticleLarge-scale datasets, tools, or models of broad utility to the cancer research community.
Review
5,000-8,000 words, 3-5 display itemsthorough, balanced reviews of important topics. Mostly commissioned. Peer-reviewed.
Perspective
5,000-7,500 words, up to 5 figuresForward-looking, thought-provoking pieces about emerging ideas in cancer biology. More speculative than Reviews.
Preview/Spotlight
≤1,200 words, 1 figure, ≤10 referencesShort commentaries highlighting significant papers in Cancer Cell or other journals. Commissioned.
Landmark Cancer Cell Papers
Papers that defined fields and changed science:
- The hallmarks of cancer immune evasion - 'three Cs' framework (Galassi et al., 2024)
- The evolving tumor microenvironment: from initiation to metastatic outgrowth (2023)
- Genomic Features of Response to Combination Immunotherapy
- Pan-cancer and TCGA-related molecular field studies
- Landmark tumor-associated macrophage and cancer-associated fibroblast characterizations
Preparing a Cancer Cell Submission?
Get pre-submission feedback from reviewers who've published in Cancer Cell and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? Human review from $1,000
Primary Fields
Related Journal Guides
- Publishing in Nature
- Publishing in Cell
- Publishing in The Lancet
- Publishing in Nature Medicine
- Publishing in Cell Metabolism
Related Articles
- Desk Rejection: What It Means, Why It Happens, and What to Do Next
- 10 Signs Your Paper Isn't Ready to Submit (Yet)
- Journal Cover Letter Template: 5 Filled-In Examples for Any Journal (2026)
- What Happens After You Submit Your Paper to a Journal
Compare Journals
中文版本
阅读中文投稿指南 →Ready to submit to Cancer Cell?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Cancer Cell editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to Cancer Cell. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to Cancer Cell reviewers.
Need field-expert depth? Human review from $1,000